盐酸表柔比星联合卡培他滨片治疗三阴性乳腺癌患者的临床效果及对血清OPN、VEGF-C的影响  

Epirubicin hydrochloride combined with capecitabine tablets on serum OPN,VEGF-C and its efficacy in triple-negative breast cancer

作　　者：徐丹英[1] 袁雁[1] 李福明[1] 

机构地区：[1]浙江省嘉兴市第二医院普外科,浙江嘉兴314000

出　　处：《中国生化药物杂志》2016年第11期118-120,共3页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的盐酸表柔比星联合卡培他滨片治疗三阴性乳腺癌患者的临床效果及对血清骨桥蛋白(osteopontin,OPN)及血管内皮生长因子-C(vascular endothelial growth factor C,VEGF-C)的影响。方法选取确诊三阴性乳腺癌患者80例,随机分成2组,每组40例。对照组给予表柔比星治疗,联合组在对照组的基础上联合卡培他滨片治疗,21 d一个疗程,治疗4个疗程。检测治疗前后血清OPN及VEGF-C水平,观察其临床疗效及不良反应事件。结果与治疗前比较,2组血清OPN及VEGF-C水平均降低(P<0.05);与对照组比较,联合组血清OPN及VEGF-C水平均较低(P<0.05),临床疗效较高(P<0.05),不良反应率较低(P<0.05)。结论卡培他滨片联合表柔比星能有效治疗三阴性乳腺癌,且显著降低血清OPN及VEGF-C水平,安全性高。Objective To explore epirubicin hydrochloride combined with capecitabine tablets on serum levels of osteopontin（ OPN）,vascular endothelial growth factor C（ VEGF-C） and its efficacy in the treatment of patients with triple-negative breast cancer. Methods 80 cases triple-negative breast cancer were selected,randomly divided into two groups,40 cases in each group. The control group were given epirubicin treatment,joint group on the basis of the control group were combined with capecitabine,21 days for a course of treatment,four courses of treatment. The serum levels of OPN and VEGF-C pre- and post-treatment were detected,the efficacy and adverse reactions were observed. Results Compared with before treatment,the serum levels of OPN and VEGF-C in two groups were lower post-treatment（ P〈0. 05）. Compared with control group,the OPN and VEGF-C levels in joint group were lower（ P〈0. 05）,the efficacy was higher and the adverse reaction was lower（ P〈0. 05）. Conclusion The epirubicin hydrochloride combined with capecitabine tablets could reduce serum OPN and VEGF-C levels in the treatment of patients with triple-negative breast cancer,with high security.

关 键 词：三阴性乳腺癌 卡培他滨 表柔比星 骨桥蛋白 

分 类 号：R737.9[医药卫生—肿瘤]